The Lifespan Limit Debate: Realists vs. Futurists Scientists are generally divided into two camps regarding the limits of human longevity. The "Realists," including demographers and evolutionary biologists like S. Jay Olshansky, argue that the human body has a "biological warranty period". They point out that the dramatic increases in life expectancy seen in the 20th century—largely driven by curing childhood and infectious diseases—have slowed significantly. Realists posit that the human lifespan is naturally capped around 115 to 125 years, and that modern medicine is currently just "manufacturing survival time" by treating the symptoms of age-related decay rather than halting the biological clock.

Conversely, "Futurists" and prominent geneticists, such as Harvard’s David Sinclair, believe that the first person to live to 150 has already been born. This camp views aging not as an inevitable thermodynamic decay, but as a treatable disease or a "software" error characterized by the loss of epigenetic information. They argue that with the right biological interventions, the human body can be reprogrammed and repaired, making a 150-year lifespan a viable medical reality. (However, extreme mythological claims of humans living for centuries, such as isolated ascetics living to 1,700, remain biological, immunological, and psychological impossibilities.)

Lifespan vs. Healthspan and the "Compression of Morbidity" A crucial distinction in longevity research is the difference between lifespan (the total years a person is alive) and healthspan (the years lived in good health, free from chronic disease and disability). Currently, modern medicine excels at preventing premature death but often expands the "morbidity span"—the period of life spent managing debilitating illnesses. Globally, there is an average gap of 9 to 10 years between a person's healthspan and their total lifespan.

The Biotechnological Toolkit To achieve these goals, billions of dollars are being invested in a new wave of anti-aging therapeutics and biotechnology startups. The most promising interventions include:

• Cellular Reprogramming: Using "Yamanaka factors" to reset the epigenetic markers of older cells, effectively turning back their biological clock to restore youthful tissue function.
• mTOR Inhibitors (Rapamycin): Drugs like rapamycin mimic the life-extending effects of caloric restriction, prompting cells to enter a "maintenance" mode and clear out misfolded proteins and damaged organelles through a process called autophagy.
• Senolytics: These are drugs designed to selectively hunt and destroy "zombie" senescent cells—damaged cells that stop dividing but secrete toxic, inflammatory chemicals that accelerate systemic aging.
• NAD+ Boosters: Supplements like Nicotinamide Riboside (NR) aim to restore cellular energy metabolism, which declines precipitously with age.
• Synergistic Sequencing: Recent hypotheses suggest that the order of these treatments matters immensely. For instance, a sequenced protocol of restoring cellular energy (NAD+), followed by cleanup (Rapamycin), and finally removal of dead cells (Senolytics) may produce superior rejuvenation outcomes.

Socio-Economic and Ethical Implications If human lifespan reaches 150 years, the societal shifts would be unprecedented. The traditional three-stage life model—education, 40 years of work, and retirement—would collapse, requiring a transition to "multi-stage" lives with extended or multiple careers. Social security and pension systems would face insolvency due to massive "longevity risk" (people outliving their assets).